This multisite study was conducted to compare the efficacy and tolerability of combination treatment with clozapine plus aripiprazole versus combination treatment with clozapine plus haloperidol in patients with schizophrenia who do not have an optimal response to clozapine. Patients continued to take clozapine and were randomly assigned to receive daily augmentation with aripiprazole or haloperidol. Physicians prescribed the allocated treatments according to usual clinical care. Withdrawal from allocated treatment within 3 months was the primary outcome. Secondary outcomes included severity of symptoms on the Brief Psychiatric Rating Scale and antipsychotic subjective tolerability on the Liverpool University Neuroleptic Side Effect Rating Scale. A total of 106 patients with schizophrenia were randomly assigned to treatment. After 3 months, we found no difference in the proportion of patients who discontinued treatment between the aripiprazole and haloperidol groups (13.2% vs 15.1%, P = 0.780). The 3-month change of the Brief Psychiatric Rating Scale total score was similar in the aripiprazole and haloperidol groups (-5.9 vs -4.4 points, P = 0.523), whereas the 3-month decrease of the Liverpool University Neuroleptic Side Effect Rating Scale total score was significantly higher in the aripiprazole group than in the haloperidol group (-7.4 vs -2.0 points, P = 0.006). These results suggest that augmentation of clozapine with aripiprazole offers no benefit with regard to treatment withdrawal and overall symptoms in schizophrenia compared with augmentation with haloperidol. However, an advantage in the perception of adverse effects with aripiprazole treatment may be meaningful for patients.

Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial

BERARDI, DOMENICO;MENCHETTI, MARCO;
2011

Abstract

This multisite study was conducted to compare the efficacy and tolerability of combination treatment with clozapine plus aripiprazole versus combination treatment with clozapine plus haloperidol in patients with schizophrenia who do not have an optimal response to clozapine. Patients continued to take clozapine and were randomly assigned to receive daily augmentation with aripiprazole or haloperidol. Physicians prescribed the allocated treatments according to usual clinical care. Withdrawal from allocated treatment within 3 months was the primary outcome. Secondary outcomes included severity of symptoms on the Brief Psychiatric Rating Scale and antipsychotic subjective tolerability on the Liverpool University Neuroleptic Side Effect Rating Scale. A total of 106 patients with schizophrenia were randomly assigned to treatment. After 3 months, we found no difference in the proportion of patients who discontinued treatment between the aripiprazole and haloperidol groups (13.2% vs 15.1%, P = 0.780). The 3-month change of the Brief Psychiatric Rating Scale total score was similar in the aripiprazole and haloperidol groups (-5.9 vs -4.4 points, P = 0.523), whereas the 3-month decrease of the Liverpool University Neuroleptic Side Effect Rating Scale total score was significantly higher in the aripiprazole group than in the haloperidol group (-7.4 vs -2.0 points, P = 0.006). These results suggest that augmentation of clozapine with aripiprazole offers no benefit with regard to treatment withdrawal and overall symptoms in schizophrenia compared with augmentation with haloperidol. However, an advantage in the perception of adverse effects with aripiprazole treatment may be meaningful for patients.
Barbui C.; Accordini S.; Nosè M.; Stroup S.; Purgato M.; Girlanda F.; Esposito E.; Veronese A.; Tansella M.; Cipriani A.; CHAT (Clozapine Haloperidol Aripiprazole Trial) Study Group […; Losavio T.; Percudani M.; Aldini F.; Appino M.G.; Artioli P.; Barale F.; Beneduce R.; Berardi D.; Bertolazzi G.; Biancosino B.; Bisogno A.; Bivi R.; Bogetto F.; Boso M.; Bozzani A.; Bucolo P.; Casale M.; Cascone L.; Ciammella L.; Cicolini A.; Cipresso G.; Colombo P.; Dal Santo B.; De Francesco M.; Di Lorenzo G.; Di Munzio W.; Erlicher A.; Ferrannini L.; Ferrato F.; Ferro A.; Fragomeno N.; Fricchione Parise V.; Frova M.; Gardellin F.; Garzotto N.; Giambartolomei A.; Giupponi G.; Grassi L.; Grazian N.; Grecu L.; Guerrini G.; Laddomada F.; Lazzarin E.; Lintas C.; Malchiodi F.; Malvini L.; Marchiaro L.; Marsilio A.; Mauri M.C.; Mautone A.; Menchetti M.; Migliorini G.; Mollica M.; Moretti D.; Mulè S.; Nicholau S.; Nosè F.; Occhionero G.; Pacilli A.M.; Pecchioli S.; Petrosemolo P.; Piantato E.; Piazza C.; Pontarollo F.; Pycha R.; Quartesan R.; Rillosi L.; Risso F.; Rizzo R.; Rocca P.; Roma S.; Rossattini M.; Rossi G.; Sala A.; Santilli C.; Saraò G.; Sarnicola A.; Sartore F.; Scarone S.; Sciarma T.; Siracusano A.; Strizzolo S.; Targa G.; Tasser A.; Tomasi R.; Travaglini R.; Valentini C.; Ziero S. …]
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11585/118837
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 31
  • ???jsp.display-item.citation.isi??? 19
social impact